最新の財務諸表(Form-10K)によると、ProUroCare Medical Incの総資産は$0で、純損失は$-2です。
PUMDの主要な財務比率は何ですか?
ProUroCare Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
ProUroCare Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
ProUroCare Medical Inc の最大収益セグメントは Pharmaceutical で、最新の利益発表における収益は 1,716,861,688 です。地域別に見ると、China が ProUroCare Medical Inc の主要市場であり、収益は 1,704,167,078 です。
ProUroCare Medical Incは収益を上げていますか?
いいえ、最新の財務諸表によると、ProUroCare Medical Incの純損失は$-2です。
ProUroCare Medical Incに負債はありますか?
はい、ProUroCare Medical Incの負債は4です。
ProUroCare Medical Incの発行済株式数は何株ですか?
ProUroCare Medical Incの総発行済株式数は18.27株です。
主要データ
前終値
$0.0001
始値
$0.0002
当日レンジ
$0.0001 - $0.0002
52週レンジ
$0.0001 - $0.0002
取引高
26.1K
平均取引高
368
配当利回り
--
1株当たり利益(TTM)
-0.14
時価総額
$1.8K
PUMDとは何ですか?
ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.